Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS) & Orexigen Therapeutics, Inc. (OREX): What’s Weight Loss For Now?

Page 1 of 2

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)It wasn’t that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing weight was a vanity issue. Doctors were reluctant to prescribe them, the FDA wouldn’t approve them unless they had squeaky-clean safety records, and insurers wouldn’t pay for them.

The tides appear to be changing.

After getting rejected once, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘ Belviq and VIVUS, Inc. (NASDAQ:VVUS)‘  Qsymia were both approved by the FDA last year. And the FDA seems open to approving a third drug, Orexigen Therapeutics, Inc. (NASDAQ:OREX)‘s Contrave.

Getting FDA approval is a necessary step, but it isn’t sufficient to gain blockbuster sales. VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s marketing partner Eisai have to convince doctors to prescribe the drugs and insurers to cover them.

VIVUS, Inc. (NASDAQ:VVUS) is making progress. On its first-quarter conference call, the company said 34% of privately insured lives cover Qsymia. Its goal is to have coverage for half of privately insured patients by the end of the year.

Endocrinologist endorsed
Obesity drugs are included in the latest version of the American Association of Clinical Endocrinologist Comprehensive Diabetes Management Algorithm, which endocrinologists and general practitioners use as a guide to determine how to treat diabetics and those who may become diabetic.

Listed after lifestyle modifications — eating less and working out more — the algorithm suggests using Belviq, Qsymia, Roche‘s Xenical, or phentermine, the safer part of phen-fen that’s available as a generic. The association clearly sees a connection between obesity and type 2 diabetes, with weight loss being an important method for controlling diabetes.

Spending money to save more
From an insurer’s perspective, it only makes sense to cover obesity medications if patients are willing to cover the added expense with higher premiums or if the expense now can help lower medical costs, thus keeping premiums down.

Higher premiums might be an option for some plans, especially for employer-sponsored health insurance, where the employers could benefit from increased productivity from healthier employees.

It’s clear insurers could save money by increasing weight loss. According to a study by the Campaign to End Obesity, increases in obesity rates are responsible for $74.6 billion in higher spending by private health insurers.

But those benefits from losing weight are seen years down the line. The study recommends looking out 25 years. How many people are going to have the same insurance now as they will 25 years from now?

Page 1 of 2
Loading Comments...